Pliant Therapeutics (PLRX) Revenue & Revenue Breakdown
Pliant Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.58M
Pliant Therapeutics Revenue by Period
Pliant Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.58M | -83.69% |
| 2022-12-31 | $9.69M | 27.91% |
| 2021-12-31 | $7.57M | -81.89% |
| 2020-12-31 | $41.82M | -26.70% |
| 2019-12-31 | $57.05M | 100.00% |
| 2018-12-31 | - | - |
Pliant Therapeutics generated $1.58M in revenue during NA 2023, up -83.69% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Pliant Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $4.84M | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $248.00K | -81.38% |
| 2023-03-31 | $1.33M | -32.21% |
| 2022-12-31 | $1.97M | 32.59% |
| 2022-09-30 | $1.48M | -70.29% |
| 2022-06-30 | $4.99M | 299.44% |
| 2022-03-31 | $1.25M | -37.52% |
| 2021-12-31 | $2.00M | 24.16% |
| 2021-09-30 | $1.61M | -10.01% |
| 2021-06-30 | $1.79M | -17.71% |
| 2021-03-31 | $2.17M | -51.31% |
| 2020-12-31 | $4.46M | -7.25% |
| 2020-09-30 | $4.81M | 33.72% |
| 2020-06-30 | $3.60M | -87.56% |
| 2020-03-31 | $28.94M | -49.28% |
| 2019-12-31 | $57.05M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-03-31 | - | - |
Pliant Therapeutics generated - in revenue during Q1 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Pliant Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ACLX | Arcellx | $110.32M | $27.38M |
| ARVN | Arvinas | $78.50M | $76.50M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| BDTX | Black Diamond Therapeutics | - | - |
| INZY | Inozyme Pharma | - | - |
| DYN | Dyne Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| PASG | Passage Bio | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| ETNB | 89bio | - | - |
PLRX Revenue FAQ
What is Pliant Therapeutics’s yearly revenue?
Pliant Therapeutics's yearly revenue for 2023 was $1.58M, representing a decrease of -83.69% compared to 2022. The company's yearly revenue for 2022 was $9.68M, representing an increase of 27.91% compared to 2021. PLRX's yearly revenue for 2021 was $7.57M, representing a decrease of -81.89% compared to 2020.
What is Pliant Therapeutics’s quarterly revenue?
Pliant Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $4.84M, a 100.00% increase from the previous quarter (Q3 2023), and a 146.31% increase year-over-year (Q4 2022). PLRX's quarterly revenue for Q3 2023 was $0, a -100.00% decrease from the previous quarter (Q2 2023), and a -100.00% decrease year-over-year (Q3 2022).
What is Pliant Therapeutics’s revenue growth rate?
Pliant Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -79.13%, and for the last 5 years (2019-2023) was -97.23%.